Scapa Group rises as revenues soar

By
0 mins. to read
Scapa Group rises as revenues soar
Master Investor Magazine

Master Investor Magazine 54Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed medical and industrial adhesives company Scapa Group (LON:SCPA) has seen its share price climb by 5.61% to 207p (as of 15:20 BST) after statutory revenues for the half year ended 30th September rose by 14.3%. Statutory profits for the period are expected to be 17% below last year, due to the loss of the ConvaTec contracts.

The healthcare division continues to drive the improvement in sales, and management said that the second half would see further uplift from new products and technology transfers.

On 30th July at 1pm we’ll be holding the next live Q&A webinar with the Master Investor himself, Jim Mellon. Please share a question for Jim below and we’ll try to answer as many as possible in the live webinar. Sign up for the webinar here.

Are you interested in joining Jim's webinar?


Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *